만성 특발성 두드러기 - 시장 인사이트, 역학, 시장 예측(2036년)

Key Highlights:

• The Chronic Spontaneous Urticaria market size in the 7MM was valued at approximately USD 2000 million in 2025 and is projected to grow significantly over the forecast period from 2026 to 2036.
• The market size of CSU in the US was approximately USD 1 billion in 2025 and is expected to increase at a CAGR of 15% during the forecast period driven by the increasing awareness of the disease and the launch of the emerging therapy.
• The total market size of CSU in EU4 and the UK was calculated to be approximately USD 600 million in 2025, which was nearly 30% of the total market revenue for the 7MM.

Chronic Spontaneous Urticaria Market and Epidemiology Analysis

• According to DelveInsight's estimates, the total diagnosed prevalent cases of chronic urticaria in the 7MM were approximately 4.8 million in 2025, with these numbers anticipated to increase by 2036.
• The Chronic Spontaneous Urticaria treatment market is projected to see consistent growth, with a robust compound annual growth rate (CAGR) anticipated from 2026 to 2036. This expansion across the 7MM will be driven by the introduction of innovative therapies, barzolvolimab (CDX-0159), LOU064 (remibrutinib), rilzabrutinib, povorcitinib, and briquilimab, among others. Additionally, the rising prevalence of Chronic Spontaneous Urticaria, driven by factors such as an aging population, increased exposure to environmental irritants, underlying autoimmune dysregulation, and improved diagnostic awareness among healthcare professionals, will further support market growth.
• The recent approval of DUPIXENT (dupilumab) by the US FDA, along with its earlier approval in Japan by the MHLW, marks a notable shift in the treatment landscape, introducing a targeted therapies that is likely to drive market competition and influence the adoption.
• Celldex Therapeutics, Novartis, Sanofi, Incyte, Jasper Therapeutics, and Evommune, among others are progressing their assets through various Chronic Spontaneous Urticaria clinical trials phases, driving innovation in the chronic pruritus market and creating significant growth opportunities.

DelveInsight's "Chronic Spontaneous Urticaria (Chronic Spontaneous Urticaria) Market Insights, Epidemiology, and Market Forecast 2036" report delivers an in-depth understanding of Chronic Spontaneous Urticaria, historical and forecasted epidemiology, as well as the Chronic Spontaneous Urticaria therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Chronic Spontaneous Urticaria therapeutics market report provides current treatment practices, emerging Chronic Spontaneous Urticaria drugs, Chronic Spontaneous Urticaria market share of individual therapies, and current and forecasted 7MM Chronic Spontaneous Urticaria market size from 2022 to 2036. The report also covers Chronic Spontaneous Urticaria treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the Chronic Spontaneous Urticaria therapeutics market potential.

Key Factors Driving the Chronic Spontaneous Urticaria Market

Growing Chronic Spontaneous Urticaria Prevalence

According to DelveInsight's estimates, the total diagnosed prevalent cases of chronic urticaria in the 7MM were approximately 4.5 million in 2024, with these numbers anticipated to increase by 2034.

DUPIXENT's Monopoly in the CSU Market

The recent approval of DUPIXENT (dupilumab) by the US FDA, along with its earlier approval in Japan by the MHLW, marks a notable shift in the treatment landscape, introducing targeted therapies that are likely to drive market competition and influence the adoption.

Growing CSU Clinical Trial Activity

The CSU treatment pipeline is increasingly competitive, featuring several promising candidates at different stages of development, including barzolvolimab (CDX-0159), remibrutinib (LOU064), rilzabrutinib, povorcitinib, and briquilimab, among others.

Chronic Spontaneous Urticaria Understanding and Treatment Algorithm

Urticaria is a common and heterogeneous inflammatory skin disorder with or without associated angioedema. It presents with wheals, angioedema, or both due to activation and degranulation of skin mast cells, followed by the release of histamine and other mediators leading to sensory nerve activation, vasodilatation, plasma extravasation, and cellular recruitment. It is classified as acute or chronic, depending on whether the onset of episodes lasts for less or >6 weeks, respectively.

Chronic urticaria is spontaneous or inducible, lasts >6 weeks, and persists for >1 year. It impacts the quality of life and is linked to psychiatric comorbidities and high healthcare costs, often causing huge socio-economic distress for the patients. In contrast to Chronic Spontaneous Urticaria, where the cause is unknown, chronic inducible urticaria has definite and subtype-specific triggers that induce signs and symptoms.

Chronic Spontaneous Urticaria diagnosis

The diagnosis is based on a physical examination and medical history. Additional tests are performed to rule out underlying causes or to identify triggers, such as blood tests, allergy tests, or skin biopsies. Screening tests for thyroid function and antithyroid peroxidase and antithyroglobulin antibodies are recommended. Positive autologous serum skin test (ASST) and in vitro testing of the patient's serum for the anti-FCeRIa or the anti-IgE autoantibodies by basophil histamine release assay (BHRA) is also recommended.

Chronic Spontaneous Urticaria treatment

Chronic Spontaneous Urticaria management follows a stepwise approach aimed at complete symptom control and quality of life improvement. First-line treatment consists of second-generation H1-antihistamines due to their safety, while first-generation agents are discouraged. For non-responders, up-dosing H1-antihistamines up to fourfold is advised, with optional H2-antihistamines, though evidence for the latter is inconsistent.

Omalizumab, an anti-IgE monoclonal antibody, is the preferred second-line option for antihistamine-refractory Chronic Spontaneous Urticaria and is effective, well-tolerated, and suitable for long-term use. Cyclosporine may be added in severe, treatment-resistant cases but is limited by safety concerns. Short courses of systemic corticosteroids can manage acute flares, but long-term use is discouraged. Leukotriene receptor antagonists, particularly montelukast, offer modest adjunctive benefit.

Chronic Spontaneous Urticaria Epidemiology

As the Chronic Spontaneous Urticaria market is derived using a patient-based model, the Chronic Spontaneous Urticaria epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented total diagnosed prevalent cases of chronic urticaria, type-specific cases of chronic urticaria, gender-specific cases of Chronic Spontaneous Urticaria, age-specific cases of Chronic Spontaneous Urticaria, and severity-specific cases of Chronic Spontaneous Urticaria in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2022 to 2036.

Key Findings from Chronic Spontaneous Urticaria Epidemiological Analyses and Forecast

• According to DelveInsight's estimates, the total diagnosed prevalent cases of chronic urticaria in the 7MM were approximately 4.8 million in 2025, with these numbers anticipated to increase by 2036.
• Among the 7MM, the US accounted for nearly 19% of the total diagnosed prevalent cases of chronic urticaria, with around 920,000 cases in 2025. These cases are expected to change during the forecast period (2026-2036). EU4 and the UK accounted for approximately 39% of the total chronic urticaria cases, while Japan accounted for around 42% in 2025.
• According to DelveInsight's age-specific prevalence estimates, in EU4 and the UK, the age group >=60 years represented the largest number of diagnosed CSU cases in 2025, with nearly 450,000 cases, followed by the 50-59 years age group, with around 250,000 cases.
• The US accounted for approximately 610,000 diagnosed prevalent cases of CSU in 2025, and these cases are projected to increase by 2036.
• In 2025, among EU4 and the UK, Germany reported the highest number of diagnosed prevalent cases of CSU with approximately 390,000 cases, while Spain reported the lowest with approximately 190,000 cases.
• Japan accounted for nearly 37% of the total diagnosed prevalent CSU cases across the 7MM in 2025

Chronic Spontaneous Urticaria Epidemiology Segmentation

• Total Diagnosed Prevalent Cases of Chronic Urticaria
• Type-specific Cases of Chronic Urticaria
• Gender-specific Cases of Chronic Spontaneous Urticaria
• Age-specific Cases of Chronic Spontaneous Urticaria
• Severity-specific Cases of Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria Market Recent Developments and Breakthroughs

• In January 2026, Jasper Therapeutics reported updated results from the Phase Ib/IIa BEACON study and its open-label extension showing that briquilimab delivered sustained disease control in CSU. Additional patients achieved complete responses and marked reductions in UAS7 scores at 12 weeks.
• In November 2025, the European Commission has approved DUPIXENT (dupilumab) for the treatment of moderate-to-severe CSU in adult and adolescent patients 12 years and above with inadequate response to histamine-1 antihistamines (H1AH) and who are naive to anti- immunoglobulin-E (IgE) therapy for CSU. Eligible patients can use DUPIXENT as a first-line targeted treatment option.

Chronic Spontaneous Urticaria Drug Analysis

The drug chapter segment of the Chronic Spontaneous Urticaria report encloses a detailed analysis of Chronic Spontaneous Urticaria marketed Chronic Spontaneous Urticaria market drugs and mid to late-stage (Phase III and Phase II) pipeline Chronic Spontaneous Urticaria drugs. It also helps understand the Chronic Spontaneous Urticaria clinical trials details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Chronic Spontaneous Urticaria Drugs

DUPIXENT (dupilumab): Sanofi/Regeneron Pharmaceuticals

DUPIXENT (dupilumab) is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by specifically binding to the IL-4Ra subunit shared by the IL-4 and IL-13 receptor complexes. Dupilumab inhibits IL-4 signaling via the 'Type I' receptor and both IL-4 and IL-13 signaling through the 'Type II receptor.' DUPIXENT is approved for multiple indications, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis.

DUPIXENT was first approved for the treatment of Chronic Spontaneous Urticaria in February 2024 in Japan, becoming the first country globally to authorize its use for this indication. The approval was based on results from a Phase III trial that demonstrated a significant reduction in itch compared to placebo. Subsequently, in April 2025, the US approved DUPIXENT as the first new targeted therapy for Chronic Spontaneous Urticaria in over a decade.

Emerging Chronic Spontaneous Urticaria Drugs

Barzolvolimab (CDX-0159): Celldex Therapeutics

Barzolvolimab is a humanized monoclonal antibody that selectively targets KIT, a receptor tyrosine kinase critical for mast cell survival, activation, and recruitment to tissues. Since mast cells play a key role in driving inflammation in CSU, inhibiting KIT offers a promising therapeutic approach.

Rilzabrutinib: Sanofi

Rilzabrutinib is an oral, reversible, covalent BTK inhibitor with the potential to become a first- or best-in-class therapy for several immune-mediated diseases. Targeting BTK, which is expressed in B cells and mast cells and plays a key role in immune responses, rilzabrutinib leverages Sanofi's TAILORED COVALENCY technology to achieve selective inhibition while minimizing off-target side effects.

Briquilimab: Jasper Therapeutics

Briquilimab, a Phase Ib/IIa investigational mAb, targets the SCF/CD117 (c-Kit) pathway to disrupt mast cell survival-a key driver in CSU. By blocking SCF-CD117 binding, it may reduce mast cell levels in the skin, offering potential relief for patients unresponsive to antihistamines.

Chronic Spontaneous Urticaria Drug Class Analysis

Chronic Spontaneous Urticaria is a chronic condition characterized by the recurrent appearance of hives or wheals on the skin. It is a disturbing allergic condition of the skin, where symptoms persist for more than 6 weeks. The diagnosis is based on a physical examination and medical history. Additional tests are performed to rule out underlying causes or to identify triggers, such as blood tests, allergy tests, or skin biopsies. Treating Chronic Spontaneous Urticaria is challenging, and the therapeutic goal is a reduction in disease activity, complete symptom control, and improvement in QoL. The current treatment regime aims to alleviate symptoms and prevent their recurrence. The treatment pattern typically involves a stepwise approach, starting with first-line treatments and progressing to more advanced options if necessary.

Standard-dose of second-generation H1- antihistamines are the primary class of medications used to treat Chronic Spontaneous Urticaria. They work by blocking histamine H1 receptors in the body, alleviating the symptoms of itching, redness, and swelling associated with Chronic Spontaneous Urticaria. Treatment is generally initiated with nonsedating antihistamines in the daytime and sedating antihistamines at night. H2 antihistamines are often combined with H1 to achieve better symptom control in Chronic Spontaneous Urticaria and are added if individuals complain of indigestion or acidity. Omalizumab, an anti-IgE monoclonal antibody, is the next-in-line therapy to be given as an add-on to improve treatment efficacy. Omalizumab is approved for Chronic Spontaneous Urticaria patients age 12 years and older who remain symptomatic despite H1-antihistamine treatment. In Chronic Spontaneous Urticaria, omalizumab prevents wheal and angioedema development and improves the quality of life.

Chronic Spontaneous Urticaria Market Outlook

Chronic Spontaneous Urticaria is a disturbing allergic condition of the skin where symptoms persist for more than 6 weeks. A mast cell-driven disease is characterized by recurrent itchy wheals (hives) that may accompany angioedema. It often causes huge socio-economic distress for the patients, significantly impacting their quality of life.

Treatment patterns vary depending on the individual and their response to different medications. Various factors, such as the severity of symptoms, treatment response, and any underlying conditions, are to be considered for the most appropriate treatment plan.

The current Chronic Spontaneous Urticaria market has been segmented into different commonly used therapeutic classes based on the prevailing treatment pattern across the 7MM, which presents minor variations in the overall prescription pattern. Oral corticosteroids, prescription antihistamines, leukotriene receptor antagonists, immunosuppressive agents, omalizumab, DUPIXENT and others are the major Chronic Spontaneous Urticaria market drugs covered in the forecast model.

Key Chronic Spontaneous Urticaria companies Celldex Therapeutics' Barzolvolimab, Novartis' LOU064 (remibrutinib), and Sanofi's Rilzabrutinib (SAR444671), among others, are evaluating their lead candidates in different stages of Chronic Spontaneous Urticaria clinical trials. They aim to investigate their products to treat Chronic Spontaneous Urticaria.

• The total market size of CSU in the 7MM was approximately USD 2 billion in 2025 and is projected to increase during the forecast period (2026-2036).
• The market size of CSU in the US was approximately USD 1 billion in 2025 and is expected to increase at a CAGR of 15% during the forecast period driven by the increasing awareness of the disease and the launch of the emerging therapy.
• The total market size of CSU in EU4 and the UK was calculated to be approximately USD 600 million in 2025, which was nearly 30% of the total market revenue for the 7MM.
• Among EU4 and the UK, Germany accounted for the highest market with approximately USD 160 million in 2025, while Spain accounted for the lowest market with nearly USD 80 million in 2025.
• In 2025, the market size of CSU in Japan was nearly USD 380 million which is expected to change by 2036.

Chronic Spontaneous Urticaria Drugs Uptake

This section focuses on the uptake rate of potential Chronic Spontaneous Urticaria drugs expected to be launched in the Chronic Spontaneous Urticaria market during 2020-2034. For example, Novartis' LOU064 (remibrutinib), a BTK inhibitor, is expected to enter the US market by 2026 and is projected to have a medium uptake during the forecast period.

Chronic Spontaneous Urticaria Pipeline Development Activities

The Chronic Spontaneous Urticaria pipeline report provides insights into different Chronic Spontaneous Urticaria clinical trials within Phase III, Phase II, and Phase I. It also analyzes key Chronic Spontaneous Urticaria companies involved in developing targeted therapeutics.

Pipeline development activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Chronic Spontaneous Urticaria emerging therapies.

Latest KOL Views on Chronic Spontaneous Urticaria

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on chronic pruritus evolving treatment landscape, patient reliance on conventional Chronic Spontaneous Urticaria therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Medical Professionals, Professors, Directors, and Others.

What KOLs are saying on Chronic Spontaneous Urticaria Patient Trends?

DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers like the University of California, US, Johns Hopkins University School of Medicine, US, Oregon Health and Science University, US, University of Chicago, US, Institute of Allergology, Charite-Universitatsmedizin, Germany, University Hospital of Tours, France, Italian College of General Practitioners and Primary Care, Italy, Association of Chronic Urticaria Affected (AAUC), Spain, St James's University Hospital, Leeds, UK, Department of Dermatology, Hiroshima Citizens Hospital, Japan, and Osaka Medical and Pharmaceutical University, Japan, among others, were contacted. Their opinion helps understand and validate current and emerging Chronic Spontaneous Urticaria therapy treatment patterns or chronic pruritus market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Chronic Spontaneous Urticaria Physician's View

As per the KOLs from the US, Chronic Spontaneous Urticaria is driven by complex skin inflammation involving mast cells, eosinophils, and basophils, leading to persistent wheals and angioedema that impair quality of life. While targeted therapies like omalizumab and dupilumab offer symptom relief, they do not address the underlying immune imbalance. Deeper insights into Chronic Spontaneous Urticaria pathogenesis are essential to enable curative, mechanism-based treatments.

As per the KOLs from France, the second-generation H1-antihistamines are used as the 1L of treatment for Chronic Spontaneous Urticaria. Increasing the dose of H1-antihistamines is recommended if the condition is not adequately controlled. Moreover, additional medications, primarily omalizumab and cyclosporine, added to treatment with antihistamines and medicines, are part of the 2L and 3L treatment therapy, respectively.

As per the KOLs from Japan, the absence of reliable predictive biomarkers in Chronic Spontaneous Urticaria limits clinicians' ability to tailor treatment, often resulting in prolonged trial-and-error with antihistamines before escalating to biologics. While markers like CRP and D-dimer correlate with disease activity, their low predictive value hinders early intervention, delaying effective control in a substantial subset of patients. Bridging this gap is critical to advancing personalized care in Chronic Spontaneous Urticaria.

Chronic Spontaneous Urticaria Report Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Attribute analysis analyzes multiple emerging Chronic Spontaneous Urticaria therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

To analyze the effectiveness of these Chronic Spontaneous Urticaria therapies, have calculated their attributed analysis by giving them scores based on their ability to improve atrial and ventricular dimension/function and ability to regulate heart rate.

Further, the therapies' safety is evaluated wherein the adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials, which directly affects the safety of the molecule in the upcoming trials. It sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging Chronic Spontaneous Urticaria therapies are decided.

Chronic Spontaneous Urticaria Market Access and Reimbursement

DUPIXENT My Way Copay Card

The DUPIXENT My Way Co-pay Card may help eligible patients cover the out-of-pocket cost of DUPIXENT. With the DUPIXENT My Way Co-pay Card, eligible, commercially insured patients may pay as little as USD 0 co-pay per fill of DUPIXENT.

Eligibility for the DUPIXENT My Way Co-pay Card requires:

• Having commercial insurance, such as through health insurance exchanges, a federal employee plan, or a state employee plan.
• Residence within the 50 US states, the District of Columbia, Puerto Rico, Guam, or the US Virgin Islands.
• A prescription for DUPIXENT for an indication approved by the US FDA.

The report provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenarios, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Chronic Spontaneous Urticaria Treatment Market Report

• The Chronic Spontaneous Urticaria therapeutics market report covers a segment of key events, an executive summary, and a descriptive overview of Chronic Spontaneous Urticaria, explaining its causes, signs and symptoms, pathogenesis, and currently available Chronic Spontaneous Urticaria therapies.
• Comprehensive insight into the epidemiology segments and forecasts, the future Chronic Spontaneous Urticaria market growth potential of diagnosis rate, disease progression, and treatment guidelines have been provided.
• Additionally, an all-inclusive account of the current and emerging Chronic Spontaneous Urticaria therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the Chronic Spontaneous Urticaria market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Chronic Spontaneous Urticaria market.

Chronic Spontaneous Urticaria Treatment Market Report Insights

• Chronic Spontaneous Urticaria Patient Population
• Chronic Spontaneous Urticaria Therapeutic Approaches
• Chronic Spontaneous Urticaria Pipeline Analysis
• Chronic Spontaneous Urticaria Market Size and Trends
• Existing and Future Market Opportunity

Chronic Spontaneous Urticaria Treatment Market Report Key Strengths

• 11 years Forecast
• The 7MM Coverage
• Chronic Spontaneous Urticaria Epidemiology Segmentation
• Key Cross Competition
• Attribute analysis
• Chronic Spontaneous Urticaria market Drugs Uptake and Key Market Forecast Assumptions

Chronic Spontaneous Urticaria Treatment Market Report Assessment

• Current Chronic Spontaneous Urticaria Treatment Practices
• Chronic Spontaneous Urticaria Unmet Needs
• Chronic Spontaneous Urticaria Pipeline Product Profiles
• Chronic Spontaneous Urticaria Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)
• Chronic Spontaneous Urticaria Market Drivers
• Chronic Spontaneous Urticaria Market Barriers

Key Questions Answered In The Chronic Spontaneous Urticaria Market Report:

Chronic Spontaneous Urticaria Market Insights

• What was the total market size of Chronic Spontaneous Urticaria, the market size of Chronic Spontaneous Urticaria by therapies, and market share (%) distribution in 2022, and what would it look like by 2036? What are the contributing factors for this growth?
• How will LOU064 (remibrutinib) affect the treatment paradigm of Chronic Spontaneous Urticaria?
• How will DUPIXENT compete with similar-class products and off-label therapies?
• Which drug is going to be the largest contributor by 2036?
• What are the pricing variations among different geographies for approved and marketed therapies?
• How would future opportunities affect the market dynamics and subsequent analysis of the associated trends

Chronic Spontaneous Urticaria Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of Chronic Spontaneous Urticaria? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Chronic Spontaneous Urticaria?
• What is the historical and forecasted Chronic Spontaneous Urticaria patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Out of the countries mentioned above, which country would have the highest diagnosed prevalent Chronic Spontaneous Urticaria population during the forecast period (2026-2036)?
• What factors are contributing to the growth of Chronic Spontaneous Urticaria cases?

Current Treatment Scenario, Chronic Spontaneous Urticaria Marketed Therapies, and Chronic Spontaneous Urticaria Emerging Therapies

• What are the current options for the treatment of Chronic Spontaneous Urticaria? What are the current Chronic Spontaneous Urticaria clinical trials and treatment guidelines for treating Chronic Spontaneous Urticaria?
• How many Chronic Spontaneous Urticaria market companies are developing Chronic Spontaneous Urticaria therapies for the treatment of Chronic Spontaneous Urticaria?
• How many emerging Chronic Spontaneous Urticaria therapies are in the mid-stage and late stage of development for treating Chronic Spontaneous Urticaria?
• What are the recent novel Chronic Spontaneous Urticaria therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What is the cost burden of current treatment on the patient?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the accessibility issues of approved Chronic Spontaneous Urticaria therapy in the US?
• What is the 7MM historical and forecasted market of Chronic Spontaneous Urticaria?

Reasons to Buy our Chronic Spontaneous Urticaria Market Forecast Report

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Chronic Spontaneous Urticaria market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• The distribution of historical and current patient share is based on real-world prescription data in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• Identifying upcoming solid Chronic Spontaneous Urticaria companies in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging Chronic Spontaneous Urticaria therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies for Chronic Spontaneous Urticaria, barriers to accessibility of approved Chronic Spontaneous Urticaria therapy, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming Chronic Spontaneous Urticaria companies can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Chronic Spontaneous Urticaria Market Overview at a Glance

• 3.1. Market Share (%) Distribution of Chronic Spontaneous Urticaria by Therapies in the 7MM in 2025
• 3.2. Market Share (%) Distribution of Chronic Spontaneous Urticaria by Therapies in the 7MM in 2036

4. Executive Summary

5. Key Events

6. Disease Background and Overview

• 6.1. Introduction
• 6.2. Signs and symptoms
• 6.3. Classification
  • 6.3.1. Classification of Urticaria Based on Its Duration and the Relevance of Eliciting Factors
• 6.4. Causes
• 6.5. Pathophysiology
• 6.6. Clinical Manifestation
• 6.7. Diagnosis
  • 6.7.1. Diagnostic Algorithm
  • 6.7.2. Diagnostic Guidelines and Recommendations
• 6.8. Treatment and Management
  • 6.8.1. Treatment for Chronic Spontaneous Urticaria
  • 6.8.2. Treatment Algorithm
  • 6.8.3. Treatment Guidelines and Recommendations

7. Methodology

8. Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Assumptions and Rationale: The 7MM
  • 8.2.1. Diagnosed Prevalent Cases of Chronic Urticaria
  • 8.2.2. Type-specific Cases of Chronic Urticaria
  • 8.2.3. Gender-specific Cases of Chronic Spontaneous Urticaria
  • 8.2.4. Age-specific Cases of Chronic Spontaneous Urticaria
  • 8.2.5. Severity-specific Cases of Chronic Spontaneous Urticaria
• 8.3. Total Diagnosed Prevalent Cases of Chronic Spontaneous Urticaria in the 7MM
• 8.4. The US
  • 8.4.1. Total Diagnosed Prevalent Cases of Chronic Urticaria in the US
  • 8.4.2. Type-specific Cases of Chronic Urticaria in the US
  • 8.4.3. Gender-specific Cases of Chronic Spontaneous Urticaria in the US
  • 8.4.4. Age-specific Cases of Chronic Spontaneous Urticaria in the US
  • 8.4.5. Severity-specific Cases of Chronic Spontaneous Urticaria in the US
• 8.5. EU4 and the UK
  • 8.5.1. Total Diagnosed Prevalent Cases of Chronic Urticaria in EU4 and the UK
  • 8.5.2. Type-specific Cases of Chronic Urticaria in EU4 and the UK
  • 8.5.3. Gender-specific Cases of Chronic Spontaneous Urticaria in EU4 and the UK
  • 8.5.4. Age-specific Cases of Chronic Spontaneous Urticaria in EU4 and the UK
  • 8.5.5. Severity-specific Cases of Chronic Spontaneous Urticaria in EU4 and the UK
• 8.6. Japan
  • 8.6.1. Total Diagnosed Prevalent Cases of Chronic Urticaria in Japan
  • 8.6.2. Type-specific Cases of Chronic Urticaria in Japan
  • 8.6.3. Gender-specific Cases of Chronic Spontaneous Urticaria in Japan
  • 8.6.4. Age-specific Cases of Chronic Spontaneous Urticaria in Japan
  • 8.6.5. Severity-specific Cases of Chronic Spontaneous Urticaria in Japan

9. Patient Journey

10. Marketed Drugs

• 10.1. DUPIXENT (dupilumab): Sanofi/Regeneron Pharmaceuticals
  • 10.1.1. Product Description
  • 10.1.2. Regulatory Milestones
  • 10.1.3. Other Developmental Activities
  • 10.1.4. Clinical Trials Information
  • 10.1.5. Safety and Efficacy

11. Emerging Drugs

• 11.1. Key Cross Competition
• 11.2. Barzolvolimab (CDX-0159): Celldex Therapeutics
  • 11.2.1. Drug Description
  • 11.2.2. Other Developmental Activities
  • 11.2.3. Clinical Trials Information
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analysts' View
• 11.3. LOU064 (remibrutinib): Novartis
  • 11.3.1. Drug Description
  • 11.3.2. Other Developmental Activities
  • 11.3.3. Clinical Trials Information
  • 11.3.4. Safety and Efficacy
  • 11.3.5. Analysts' View
• 11.4. Rilzabrutinib: Sanofi
  • 11.4.1. Drug Description
  • 11.4.2. Other Developmental Activities
  • 11.4.3. Clinical Trials Information
  • 11.4.4. Safety and Efficacy
  • 11.4.5. Analysts' View
• 11.5. Povorcitinib: Incyte
  • 11.5.1. Drug Description
  • 11.5.2. Other Developmental Activities
  • 11.5.3. Clinical Trials Information
  • 11.5.4. Safety and Efficacy
  • 11.5.5. Analysts' View
• 11.6. Briquilimab: Jasper Therapeutics
  • 11.6.1. Drug Description
  • 11.6.2. Other Developmental Activities
  • 11.6.3. Clinical Trials Information
  • 11.6.4. Safety and Efficacy
  • 11.6.5. Analysts' View
• 11.7. INF904: InflaRx
  • 11.7.1. Drug Description
  • 11.7.2. Other Developmental Activities
  • 11.7.3. Clinical Trials Information
  • 11.7.4. Safety and Efficacy
• 11.8. EVO756: Evommune
  • 11.8.1. Drug Description
  • 11.8.2. Other Developmental Activities
  • 11.8.3. Clinical Trials Information
  • 11.8.4. Safety and Efficacy
• 11.9. TAS5315: Otsuka Holdings (Taiho Pharmaceutical)
  • 11.9.1. Drug Description
  • 11.9.2. Clinical Trials Information

12. Chronic Spontaneous Urticaria - 7MM Market Analysis

• 12.1. Key Findings
• 12.2. Key Market Forecast Assumptions
  • 12.2.1. Cost Assumptions and Rebates
  • 12.2.2. Pricing Trends
  • 12.2.3. Analogue Assessment
  • 12.2.4. Launch Year and Therapy Uptake
• 12.3. Market Outlook
• 12.4. Attribute Analysis
• 12.5. Total Market Size of Chronic Spontaneous Urticaria in the 7MM
• 12.6. Market Size of Chronic Spontaneous Urticaria by Therapies in the 7MM
• 12.7. The US
  • 12.7.1. Total Market Size of Chronic Spontaneous Urticaria in the US
  • 12.7.2. Market Size of Chronic Spontaneous Urticaria by Therapies in the US
• 12.8. EU4 and the UK
  • 12.8.1. Total Market Size of Chronic Spontaneous Urticaria in EU4 and the UK
  • 12.8.2. Market Size of Chronic Spontaneous Urticaria by Therapies in EU4 and the UK
• 12.9. Japan
  • 12.9.1. Total Market Size of Chronic Spontaneous Urticaria in Japan
  • 12.9.2. Market Size of Chronic Spontaneous Urticaria by Therapies in Japan

13. Key Opinion Leaders' Views

14. Unmet Needs

15. SWOT Analysis

16. Market Access and Reimbursement

• 16.1. The United States
  • 16.1.1. Centers for Medicare & Medicaid Services (CMS)
• 16.2. EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. The United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW

17. Appendix

• 17.1. Acronyms and Abbreviations
• 17.2. Bibliography
• 17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight